Quick Answer
Jazz Pharmaceuticals plc reported Net Income Loss of -$356.15 million for the year ending 2025.
- Jazz Pharmaceuticals plc showed a decrease of -163.6% in Net Income Loss from 2024 to 2025.
- This data is from Jazz Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $75.81 million | Q2 2016: $114.50 million | Q3 2016: $89.83 million | Q4 2016: $116.69 million | Q1 2017: $86.51 million | Q2 2017: $105.60 million | Q3 2017: $63.53 million | Q4 2017: $232.21 million | Q1 2018: $45.99 million | Q2 2018: $92.32 million | Q3 2018: $149.32 million | Q4 2018: $159.47 million | Q1 2019: $85.20 million | Q2 2019: $261.90 million | Q3 2019: $102.28 million | Q4 2019: $73.99 million | Q1 2020: -$157.83 million | Q2 2020: $114.80 million | Q3 2020: $148.23 million | Q4 2020: $133.41 million | Q1 2021: $121.83 million | Q2 2021: -$363.32 million | Q3 2021: -$52.83 million | Q1 2022: $1.65 million | Q2 2022: $34.67 million | Q3 2022: -$19.65 million | Q1 2023: $69.42 million | Q2 2023: $104.44 million | Q3 2023: $146.82 million | Q1 2024: -$14.62 million | Q2 2024: $168.57 million | Q3 2024: $215.06 million | Q1 2025: -$92.54 million | Q2 2025: -$718.47 million | Q3 2025: $251.41 million.
- Over the full 17 years of available data (2009 to 2025), Jazz Pharmaceuticals plc's Net Income Loss has declined by 5,109.9%.
- Historical annual values: Fiscal year 2025: -$356.15 million | Fiscal year 2024: $560.12 million | Fiscal year 2023: $414.83 million | Fiscal year 2022: -$224.06 million | Fiscal year 2021: -$329.67 million | Fiscal year 2020: $238.62 million | Fiscal year 2019: $523.37 million | Fiscal year 2018: $447.10 million | Fiscal year 2017: $487.85 million | Fiscal year 2016: $396.83 million | Fiscal year 2015: $329.54 million | Fiscal year 2014: $58.39 million | Fiscal year 2013: $216.31 million | Fiscal year 2012: $288.59 million | Fiscal year 2011: $124.98 million | Fiscal year 2010: $32.78 million | Fiscal year 2009: -$6.84 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: